AHS 2024 | Potential of delta opioid receptors as a target for migraine

Amynah Pradhan, PhD, Washington University in St. Louis, St. Louis, MO, provides insights about δ-opioid receptors (DOR) as a therapeutic target for migraine, having been shown in pre-clinical models to have an anti-migraine-like effect. They have also been found to have a potential anti-depressant effect, which holds promise considering the link between headache and mood disorders. Unlike μ-opioid receptors, which DORs are related to, they have low abuse liability. This interview took place at the American Headache Society (AHS) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.